Gemcitabine Current Events

Gemcitabine Current Events, Gemcitabine News Articles.
Sort By: Most Viewed | Most Recent
Page 1 of 6 | 208 Results
Combination treatment improves survival for pancreatic cancer
A combination of chemotherapy drugs could double survival rates for pancreatic cancer, suggests a study published online today by The Lancet Oncology. (2005-05-09)

Chemotherapy with gemcitabine delays progression of operable pancreatic cancer
Giving pancreatic cancer patients the chemotherapy drug gemcitabine after surgery delays progression of the disease by about six months, according to new research by Japanese scientists. (2007-09-27)

2-drug combination, nab-paclitaxel and gemcitabine, improves survival in pancreatic cancer
Investigators at the Vall d´Hebron University Hospital and the Vall d'Hebron Institute of Oncology, have participated in an international phase III study, published in The New England Journal of Medicine. Results show that administering these two drugs in combination significantly improves one- and two-year survival in patients with advanced pancreatic cancer versus gemcitabine alone, the first-line treatment or most standard approach for this type of cancer to date. (2013-10-17)

Chemoradiotherapy vs. chemotherapy for locally advanced pancreatic cancer
In a study appearing in the May 3 issue of JAMA, Pascal Hammel, M.D., of Beaujon Hospital, Clichy, France and colleagues assessed whether chemoradiotherapy improves overall survival of patients with locally advanced pancreatic cancer controlled after four months of gemcitabine-based induction chemotherapy, and assessed the effect of erlotinib on survival. Gemcitabine and erlotinib are drugs used to treat cancer. (2016-05-03)

New drug substantially extends survival in pancreatic cancer
A new form of chemotherapy that destroys new blood vessels that grow around tumors has produced excellent results in a phase II trial of patients with inoperable pancreatic cancer, researchers report at the 33rd Congress of the European Society for Medical Oncology in Stockholm. (2008-09-16)

Marimastat produces comparable survival rates to chemotherapy in some advanced pancreatic cancer patients
An international team of researchers from the United States and Britain report that marimastat offers a similar survival benefit to chemotherapy in patients with non-metastatic pancreatic cancer, but with fewer side effects. A randomized clinical trial compared the effects of three different doses of marimastat, a matrix metalloproteinase inhibitor, with gemcitabine in 414 patients with advanced pancreatic cancer. (2001-07-30)

Jefferson researchers identify critical marker of response to gemcitabine in pancreatic cancer
A protein related to aggressive cancers can actually improve the efficacy of gemcitabine at treating pancreatic cancer, according to a priority report in Cancer Research, published by researchers at Thomas Jefferson University. (2009-06-04)

Study reveals why chemotherapy may be compromised in patients with pancreatic cancer
A study at The University of Texas MD Anderson Cancer Center may explain why chemotherapy drugs such as gemcitabine are not effective for many pancreatic cancer patients, and perhaps point to new approaches to treatment including enhancing gemcitabine's ability to stop tumor growth. (2015-11-11)

Gemcitabine demonstrates promise as a low toxic chemotherapeutic agent for bladder cancer
Patients with bladder cancer could benefit from treatment with gemcitabine (Gemzar®), a chemotherapeutic agent that has been used successfully to treat pancreatic cancer and non-small cell lung cancer, according to phase I trial results reported at the 38th Annual Meeting of the American Society for Clinical Oncology (ASCO) by Merrill J. Egorin, M.D., professor of medicine at University of Pittsburgh Cancer Institute. (2002-05-19)

Trend in increased survival in pancreatic cancer patients given axitinib warrants phase III trials
Patients with advanced pancreatic cancer given axitinib in addition to the standard treatment of gemcitabine show a trend towards increased survival compared with those given gemcitabine alone. The findings now require further investigation in a phase III trial. These are the conclusions of authors of an article published early online and in an upcoming edition of the Lancet. (2008-05-29)

Mayo Clinic-led study finds 2-drug combo slows advanced pancreatic cancer
The combination of the novel drug TH-302 with the standard drug gemcitabine has shown early signs of delaying the worsening of cancer in patients with advanced pancreatic cancer, a Mayo Clinic-led study has found. (2012-04-02)

Study finds that only half of a commonly used cancer drug is activated in cancer patients
According to results reported at the 40th Annual Meeting of the American Society of Clinical Oncology, only half of the delivered dose a commonly used chemotherapeutic agent may be activated in cancer patients. The study analyzed data from 31 cancer patients given 30-minute infusions of gemcitabine and found that while approximately 50 percent of the dose was likely to be converted to active metabolites, the other 50 percent was likely to be inactivated. (2004-06-08)

New boost for pancreatic cancer therapy
Scientists at Fox Chase Cancer Center are developing a new way to treat pancreatic cancer by boosting the effects of gemcitabine (Gemzar) -- the chemotherapy drug that is considered standard therapy for the disease. Although gemcitabine is the first line of defense against pancreatic cancer, many cells find ways to evade the treatment. The new research found several compounds that appear to improve the cancer-killing effect of gemcitabine. (2012-04-02)

Chemotherapy drug improves survival following surgery for pancreatic cancer
Among patients with pancreatic cancer who had surgery for removal of the cancer, treatment with the drug gemcitabine for six months resulted in increased overall survival as well as disease-free survival, compared with observation alone, according to a study in the Oct. 9 issue of JAMA. (2013-10-08)

Pancreatic cancer: Researchers find drug that reverses resistance to chemotherapy
For the first time researchers have shown that by inhibiting the action of an enzyme called TAK-1, it is possible to make pancreatic cancer cells sensitive to chemotherapy, opening the way for the development of a new drug to treat the disease. (2009-09-24)

Combination therapy may enhance gemcitabine activity
Oncologists who treat patients with pancreatic cancer may be one step closer to understanding why gemcitabine, the only currently available treatment, works in some cases but not in others, according to a paper in Cancer Discovery. (2012-02-28)

Researchers find possible new treatment strategies for pancreatic cancer
New University of Georgia research has identified a protein that can be modified to improve the effectiveness of one of the most common drugs used to treat pancreatic cancer. (2011-03-03)

Study establishes new standard of care for pancreatic cancer patients
A combination of two chemotherapy drugs -- gemcitabine and capecitabine -- should be the new standard of care for pancreatic cancer patients who have had surgery to remove their tumor. (2017-01-24)

EORTC intergroup trial opens for patients with resected head of pancreas adenocarcinoma
EORTC trial 40084-22084 has two primary objectives: To determine if adding erlotinib to gemcitabine adjuvant chemotherapy will improve survival as compared to gemcitabine alone following resection of head of pancreas adenocarcinoma, then, following adjuvant chemotherapy, to determine if concurrent fluoropyrimidine and radiotherapy improves survival for patients who have no evidence of progressive disease. (2013-06-04)

Oncolytics Biotech Inc., research collaborators demonstrate reovirus/gemcitabine
Researchers concluded that the synergistic combination of Reolysin and gemcitabine is a promising therapeutic regimen for study in clinical trials. (2007-04-17)

New combination therapy after surgery improves survival for pancreatic cancer patients
Adding the cancer-fighting drug gemcitabine to standard therapy after surgery significantly improves survival for patients with the most common form of pancreatic cancer, according to a new multicenter study led by a University of Maryland radiation oncologist. The results of the four-year Phase III clinical trial were presented June 4 at the American Society of Clinical Oncology annual meeting in Atlanta. (2006-06-04)

Chemotherapy appears to delay cancer recurrence following surgery for pancreatic cancer
Use of the drug gemcitabine for chemotherapy significantly delays the recurrence of cancer, compared to no chemotherapy, for patients following pancreatic cancer surgery, according to a study in the January 17 issue of JAMA. (2007-01-16)

In elderly patients, combination chemotherapy no more effective than individual drugs
For elderly patients with advanced non-small-cell lung cancer (NSCLC), combination chemotherapy with the drugs vinorelbine and gemcitabine appears to be no more effective than either drug alone, but is more toxic, according to a study in the March 5 issue of the Journal of the National Cancer Institute. (2003-03-04)

Drug design success propels efforts to fight HIV with a combination of 2 FDA-approved drugs
A University of Minnesota research team has developed a new delivery system for a combination of two FDA approved drugs that may serve as an effective treatment for the human immunodeficiency virus. The discovery, which allows for a combination of decitabine and gemcitabine to be delivered in pill form, marks a major step forward in patient feasibility for the drugs, which previously had been available solely via injection or intravenous therapy. (2013-08-30)

New approach improves five-year survival for pancreatic cancer patients
A University of Liverpool (UK) led clinical trial has been successful in prolonging survival for pancreatic cancer patients by at least five years as a result of a combination of chemotherapy drugs. (2017-01-24)

Comparing cancer drug effectiveness from cells to mice to man
Dartmouth researchers who studied the cancer drug gemcitabine in cell culture, mouse models and humans have shown that the drug, at administered (tolerated) dose, arrests cell growth during cancer progression. This information can lead to better understanding how gemcitabine can be combined with other drugs at identified phases to more effectively treat cancer. (2017-09-06)

Tumor-associated immune cells hinder frontline chemotherapy drug in pancreatic cancer
A frontline chemotherapy drug given to patients with pancreatic cancer is made less effective because similar compounds released by tumor-associated immune cells block the drug's action, research led by the University of Michigan Rogel Cancer Center found. (2019-03-26)

Advanced soft tissue sarcomas respond to new drug GDC-0575 combined with gemcitabine
Researchers working to find effective treatments for soft tissue sarcomas have discovered that combining a new anti-cancer drug with an existing one kills cancer cells not only in the laboratory but also in the first two patients treated with it, leading to unusually long-lasting periods without the disease progressing. Professor Antoine Italiano told the 28th EORTC-NCI-AACR Symposium that combining GDC-0575 with gemcitabine, a cancer-killing drug that is already used for treating sarcomas, proved remarkably effective. (2016-12-01)

Mayo Clinic: Nutritional supplement works against some pancreatic cancer cells in mice
The dietary supplement gamma-linoleic acid can inhibit the growth of a subset of pancreatic cancer cells and selectively promote cancer cell death in mice, a Mayo Clinic study has found. (2012-04-03)

Making science personal: Lilly Oncology to unveil 76 studies at ASCO 2007
Lilly Oncology will unveil 76 studies at the 43rd Annual Meeting of the American Society of Clinical Oncology in Chicago, Ill., from June 1-5, 2007. The company will present important data on GEMZAR, ALIMTA and enzastaurin, an investigational, oral, targeted therapy. There will also be numerous studies that continue to use GEMZAR and ALIMTA as chemotherapeutic foundations in innovative combinations with new targeted therapies. (2007-05-23)

Gene-regulatory factors shown to improve pancreatic cancer response to chemotherapy
TMDU researchers revealed that, in pancreatic cancer, the microRNAs miR-509-5p and miR-1243 can promote E-cadherin expression and thereby reduce the likelihood of cells undergoing epithelial-mesenchymal transition, or indeed reverse this transition. This ability to stop cells from adopting a phenotype linked to high migration and invasiveness was also shown to synergistically increase the cancer cell-killing efficacy of gemcitabine, which is promising for developing more effective combinatorial treatments for pancreatic cancer. (2017-08-01)

Combination therapy may improve survival for pancreatic cancer
Patients with pancreatic cancer, a historically difficult-to-treat cancer with poor survival rates, may benefit from treatments studied in an international, multi-center research trial. (2006-07-25)

Bladder-sparing treatment shows promise against cancer, maintains quality of life, UMHS study finds
A new pilot study by University of Michigan Health System researchers found combining radiation therapy and the chemotherapy drug gemcitabine may effectively treat bladder cancer without toxic reactions, while allowing many patients to preserve their bladder. (2004-07-20)

Gemcitabine and capecitabine improved overall survival in patients with advanced pancreatic cancer
The prognosis of pancreatic cancer is poor but new therapies such as gemcitabine have contributed to improving the outcome for patients. Data presented at the 13th European Conference (ECCO) revealed that using the combination of gemcitabine and capecitabine increased overall survival in some patients. (2005-11-02)

2-drug combo more effective in treating sarcomas, Moffitt Cancer Center study shows
Researchers at Moffitt Cancer Center and colleagues at the University of South Florida have found that when given together, a two-drug combination acts synergistically in test animals modeled with sarcoma tumors. They report that the drug combination of MK-1775 and gemcitabine resulted in a 70 percent decrease in the tumor volume when compared to receiving one drug or the other. (2013-04-09)

Global study shows new breast cancer drug extends patients' overall survival
Breast cancer patients with advanced disease live longer when treated with a new drug, gemcitabine, in combination with paclitaxel, a traditional drug, according to results of a landmark global phase III study presented today at the American Society of Clinical Oncology (ASCO) annual meeting. (2004-06-05)

New drug shows encouraging survival in pancreatic cancer
A phase 1 clinical trial testing a new drug in pancreatic cancer had promising initial results, report researchers from the University of Michigan Rogel Cancer Center. The trial looked at AZD1775, an inhibitor designed to block an enzyme called Wee1, which plays a role in DNA damage repair. (2019-08-14)

Fox Chase researchers reveal how pancreatic cancer cells sidestep chemotherapy
Research led by Timothy J. Yen, Ph.D., professor at Fox Chase Cancer Center, reveals that one reason pancreatic cancer can be so challenging to treat is because its cells have found a way to sidestep chemotherapy. They hijack the vitamin D receptor, normally associated with bone health, and re-purposed it to repair the damage caused by chemotherapy. (2015-01-29)

After resection, common treatment of pancreatic cancer as effective as chemotherapy drug dose
Use of gemcitabine, a drug that can be effective in treating advanced and resected pancreatic cancer, did not result in improved overall survival after pancreatic cancer resection (surgical removal) compared to patients who received fluorouracil and folinic acid, another treatment regimen that has shown effectiveness, according to a study in the Sept. 8 issue of JAMA. (2010-09-07)

Glitches in DNA repair genes predict prognosis in pancreatic cancer
Variations in mismatch repair genes can help predict treatment response and prognosis in patients with pancreatic cancer, according to research from the University of Texas M. D. Anderson Cancer Center presented today in advance of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. (2009-01-13)

Page 1 of 6 | 208 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.